SCHEMBL4816668

SCHEMBL4816668

N#Cc1ccc2c(Cc3cccc(-c4ccc(C(N)=O)cc4C(=O)OCc4ccccc4)c3)cn(Cc3ccccc3)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1D P25100 2/20 0.39
HDAC8 Q9BY41 3/20 0.39
HDAC6 Q9UBN7 3/20 0.39
HDAC1 Q13547 2/20 0.39
DRD2 P14416 1/20 0.37
HTR6 P50406 1/20 0.37
LMNA P02545 3/20 0.37
HTT P42858 2/20 0.37
F2RL3 Q96RI0 1/20 0.36
MAPT P10636 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ICMT O60725 4/20 0.35
SERPINE1 P05121 1/20 0.35
PLA2G2A P14555 1/20 0.35
PPARG P37231 1/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34
KDM1A O60341 1/20 0.34
ALDH1A1 P00352 1/20 0.34
BRD4 O60885 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4813769 0.80 HDAC1 (0.44) ADRA1DHDAC8HDAC6HDAC1LMNA
SCHEMBL29208394 0.73 LMNA (0.43) HDAC8HDAC6HDAC1DRD2HTR6
SCHEMBL4816678 0.72 HAT1 (0.37) MAPTALDH1A1
SCHEMBL4812930 0.72 PLA2G4A (0.41) HDAC8HDAC6HDAC1NPSR1PPARG
SCHEMBL4815653 0.72 SLC22A12 (0.41) PLA2G2A
SCHEMBL4812571 0.71 PLA2G4A (0.43) LMNAMAPTPLA2G2AALDH1A1
SCHEMBL4809520 0.70 CYP19A1 (0.44) HDAC8HDAC6HDAC1LMNAHTT
SCHEMBL4815125 0.70 TSHR (0.33) PPARGPPARDPPARAKDM1A
SCHEMBL4815505 0.70 TSHR (0.36) HDAC8HDAC6HDAC1LMNAMAPT
SCHEMBL4812944 0.69 PLA2G4A (0.38) HDAC8HDAC6HDAC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7417063-B2 Bicyclic heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-26 US disclosed
EP-1740538-A4 BICYCLIC HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2007-12-19 EP disclosed
EP-1740538-A2 BICYCLIC HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS Bristol-Myers Squibb Company (US) 2007-01-10 EP disclosed
WO-2005099709-A2 BICYCLIC HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-10-27 WO disclosed
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent BRISTOL-MYERS SQUIBB COMPANY 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent F12, F11, F2 ADRA1D 3477/4885HDAC8 868/4885HDAC6 3538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.